RxDoctor Payments DataLook up a doctor →

John Kim, MD

Allergy & Immunology · Medford, NJNPI 1467442384

Payments from drug & device makers

$339,125in general payments, 2019–2025

Across 1,331 payments — averaging $254.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$232K
  • Regeneron Healthcare Solutions, Inc.$61K
  • GSK$11K
  • Novartis$7K
  • AstraZeneca$7K
  • Pfizer$7K
  • plus $13K from 40 others

What the payments were for

  • Consulting fees$18,3165%
  • Speaking & faculty fees$256,91876%
  • Travel & lodging$37,19611%
  • Food & beverage$26,4608%
  • Education$2340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$339,125 in reported general payments places this provider in the 90th percentile of 135 allergy & immunology providers in New Jersey.

See all allergy & immunology providers in New Jersey

Medicare billing

Part B allowed, 2024
$159,934
Medicare patients
315
Services billed
10,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrladeyoBerotralstat Hydrochloride11$458,770
HaegardaC1 Esterase Inhibitor14$430,972
Dupixent PenDupilumab32$117,260
HizentraImmun Glob G(Igg)/Pro/Iga 0-5019$71,865
Fasenra PenBenralizumab12$68,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$66,888
XolairOmalizumab18$49,631
Breo ElliptaFluticasone/Vilanterol46$32,620
RyventCarbinoxamine Maleate22$25,404
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$22,690
Advair HfaFluticasone Propion/Salmeterol27$18,798
AlvescoCiclesonide14$16,208
Fluticasone-SalmeterolFluticasone Propion/Salmeterol77$15,806
Albuterol Sulfate HfaAlbuterol Sulfate168$12,953
Epinephrine50$10,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda, Hizentra$899$502,83833 claims
Biocryst US Sales Co., LLCOrladeyo$222$458,77011 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$11,046$107,487130 claims
AstraZenecaBreztri Aerosphere$7,095$22,69022 claims
Covis Pharma GmbHAlvesco$248$16,20814 claims
Hikma Pharmaceuticals USAEpinephrine$112$10,62850 claims
Boehringer IngelheimSpiriva Respimat$120$8,65513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 135 allergy & immunology providers in New Jersey.

Other allergy & immunology in Medford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →